MedPacto unveils topline data of vactosertib-Keytruda combo p1b2a trials - KBR
| 235980 Stock | KRW 4,650 50.00 1.06% |
About 61% of MedPacto's investor base is looking to short. The analysis of current outlook of investing in MedPacto suggests that many traders are alarmed regarding MedPacto's prospects. The current market sentiment, together with MedPacto's historical and current headlines, can help investors time the market. In addition, many technical investors use MedPacto stock news signals to limit their universe of possible portfolio assets.
MedPacto |
MedPacto unveils topline data of vactosertib-Keytruda combo p1b2a trials KBR
Read at news.google.com
 |
MedPacto Fundamental Analysis
We analyze MedPacto's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedPacto using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedPacto based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
MedPacto is rated fifth in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
MedPacto Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MedPacto stock to make a market-neutral strategy. Peer analysis of MedPacto could also be used in its relative valuation, which is a method of valuing MedPacto by comparing valuation metrics with similar companies.
Peers
MedPacto Related Equities
| 302440 | SK Bioscience | 8.65 | ||||
| 207940 | Samsung Biologics | 0.62 | ||||
| 144510 | Green Cross | 0.20 | ||||
| 235980 | MedPacto | 1.06 | ||||
| 334970 | Prestige Biologics | 1.92 | ||||
| 086890 | ISU Abxis | 2.92 | ||||
| 226950 | OliX PharmaceuticalsI | 3.11 |
Complementary Tools for MedPacto Stock analysis
When running MedPacto's price analysis, check to measure MedPacto's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedPacto is operating at the current time. Most of MedPacto's value examination focuses on studying past and present price action to predict the probability of MedPacto's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedPacto's price. Additionally, you may evaluate how the addition of MedPacto to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |